Structural modifications of N-arylamide oxadiazoles: Identification of N-arylpiperidine oxadiazoles as potent and selective agonists of CB2.

[1]  F. Ito,et al.  The SAR studies of novel CB2 selective agonists, benzimidazolone derivatives. , 2008, Bioorganic & medicinal chemistry letters.

[2]  Michael Koblish,et al.  Sulfamoyl benzamides as novel CB2 cannabinoid receptor ligands. , 2008, Bioorganic & medicinal chemistry letters.

[3]  Bie M. P. Verbist,et al.  5-Sulfonyl-benzimidazoles as selective CB2 agonists. , 2008, Bioorganic & medicinal chemistry letters.

[4]  B. Dymock,et al.  Arylsulfonamide CB2 receptor agonists: SAR and optimization of CB2 selectivity. , 2008, Bioorganic & medicinal chemistry letters.

[5]  E. Högenauer,et al.  Latest advances in the cannabinoids , 2007 .

[6]  M. Cascio,et al.  New 1,8-naphthyridine and quinoline derivatives as CB2 selective agonists. , 2007, Bioorganic & medicinal chemistry letters.

[7]  Y. Toda,et al.  N-Alkylidenearylcarboxamides as new potent and selective CB(2) cannabinoid receptor agonists with good oral bioavailability. , 2007, Bioorganic & medicinal chemistry letters.

[8]  D. Pagé,et al.  New 1,2,3,4-tetrahydropyrrolo[3,4-b]indole derivatives as selective CB2 receptor agonists. , 2007, Bioorganic & medicinal chemistry letters.

[9]  G. Muccioli.  Blocking the Cannabinoid Receptors: Drug Candidates and Therapeutic Promises , 2007, Chemistry & biodiversity.

[10]  S. Hitchcock,et al.  Targeting cannabinoid agonists for inflammatory and neuropathic pain , 2007, Expert opinion on investigational drugs.

[11]  I. Chessell,et al.  Discovery of 2-[(2,4-dichlorophenyl)amino]-N-[(tetrahydro- 2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- 5-pyrimidinecarboxamide, a selective CB2 receptor agonist for the treatment of inflammatory pain. , 2007, Journal of medicinal chemistry.

[12]  K. Valenzano,et al.  The role of the cannabinoid CB2 receptor in pain transmission and therapeutic potential of small molecule CB2 receptor agonists. , 2007, Current medicinal chemistry.

[13]  P. Lazzari,et al.  Tricyclic pyrazoles. 4. Synthesis and biological evaluation of analogues of the robust and selective CB2 cannabinoid ligand 1-(2',4'-dichlorophenyl)-6-methyl-N-piperidin-1-yl-1,4-dihydroindeno[1,2-c]pyrazole-3-carboxamide. , 2006, Journal of medicinal chemistry.

[14]  A. Vannacci,et al.  Design, synthesis, and biological evaluation of new 1,8-naphthyridin-4(1H)-on-3-carboxamide and quinolin-4(1H)-on-3-carboxamide derivatives as CB2 selective agonists. , 2006, Journal of medicinal chemistry.

[15]  A. Poso,et al.  Synthesis and SAR studies of 2-oxoquinoline derivatives as CB2 receptor inverse agonists. , 2006, Journal of medicinal chemistry.

[16]  Philippe Chavatte,et al.  Novel 4-oxo-1,4-dihydroquinoline-3-carboxamide derivatives as new CB2 cannabinoid receptors agonists: synthesis, pharmacological properties and molecular modeling. , 2006, Journal of medicinal chemistry.

[17]  Ken Mackie,et al.  Cannabinoid receptors as therapeutic targets. , 2006, Annual review of pharmacology and toxicology.

[18]  J. Cheetham,et al.  An Automated Screening Assay for Determination of Aqueous Equilibrium Solubility Enabling SPR Study During Drug Lead Optimization , 2005 .

[19]  C. Fowler,et al.  The endocannabinoid system: drug targets, lead compounds, and potential therapeutic applications. , 2005, Journal of medicinal chemistry.

[20]  T. Nevalainen,et al.  Targeting the cannabinoid CB2 receptor: mutations, modeling and development of CB2 selective ligands. , 2005, Current medicinal chemistry.

[21]  S. Narula,et al.  Triaryl bis-sulfones as a new class of cannabinoid CB2 receptor inhibitors: identification of a lead and initial SAR studies. , 2005, Bioorganic & medicinal chemistry letters.

[22]  Paul A Keller,et al.  Control of hepatitis C: a medicinal chemistry perspective. , 2005, Journal of medicinal chemistry.

[23]  R. Hampson,et al.  Cannabinoid physiology and pharmacology: 30 years of progress , 2004, Neuropharmacology.

[24]  T. Vanderah,et al.  CB2 cannabinoid receptor-mediated peripheral antinociception , 2001, Pain.

[25]  M. Tramèr,et al.  Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review , 2001, BMJ : British Medical Journal.

[26]  N. Kaminski,et al.  Inhibition of the cAMP signaling cascade via cannabinoid receptors: a putative mechanism of immune modulation by cannabinoid compounds. , 1998, Toxicology letters.

[27]  N. Kaminski,et al.  Inhibition of the cyclic AMP signaling cascade and nuclear factor binding to CRE and kappaB elements by cannabinol, a minimally CNS-active cannabinoid. , 1998, Biochemical pharmacology.

[28]  M. Johnson,et al.  Selective and Potent Analgetics Derived from Cannabinoids , 1981, Journal of clinical pharmacology.

[29]  Stephen L. Buchwald,et al.  New insights into Xantphos/Pd-Catalyzed C-N bond forming reactions : A structural and kinetic study , 2006 .

[30]  A. Molleman,et al.  Cannabinoid signalling (review) , 2006 .

[31]  B. Martin,et al.  Neurobiology of marijuana abuse. , 1992, Trends in pharmacological sciences.